Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Biocartis Group NV Company Overview 6
Biocartis Group NV Company Snapshot 6
Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview 6
Biocartis Group NV – Pipeline Analysis Overview 9
Biocartis Group NV – Key Facts 9
Biocartis Group NV – Major Products and Services 10
Biocartis Group NV Pipeline Products by Development Stage 11
Biocartis Group NV Pipeline Products Overview 14
EGFR Colon Cancer Test 14
EGFR Colon Cancer Test Product Overview 14
Idylla Blood Stream Infections Panel 15
Idylla Blood Stream Infections Panel Product Overview 15
Idylla ctEGFR Assay 16
Idylla ctEGFR Assay Product Overview 16
Idylla Extended KRAS Mutation Test 17
Idylla Extended KRAS Mutation Test Product Overview 17
Idylla Extended NRAS Mutation Test 18
Idylla Extended NRAS Mutation Test Product Overview 18
Idylla HPV Test – Head & Neck Cancer 19
Idylla HPV Test – Head & Neck Cancer Product Overview 19
Idylla Immuno Tx Panel Test 20
Idylla Immuno Tx Panel Test Product Overview 20
Idylla KRAS Mutation Test 21
Idylla KRAS Mutation Test Product Overview 21
Idylla Liquid Biopsy EGFR Mutation Assay 22
Idylla Liquid Biopsy EGFR Mutation Assay Product Overview 22
Idylla Liquid Biopsy Test – Breast Cancer 23
Idylla Liquid Biopsy Test – Breast Cancer Product Overview 23
Idylla Meningitis Assay 24
Idylla Meningitis Assay Product Overview 24
Idylla MERS Assay 25
Idylla MERS Assay Product Overview 25
Idylla MSI Test 26
Idylla MSI Test Product Overview 26
Idylla Multiplex Respiratory Panel 27
Idylla Multiplex Respiratory Panel Product Overview 27
Idylla Neuro Panel Test 28
Idylla Neuro Panel Test Product Overview 28
Idylla Neurological Disease Assay 29
Idylla Neurological Disease Assay Product Overview 29
Idylla NGS Prep Panel – Pan-Tumor 30
Idylla NGS Prep Panel – Pan-Tumor Product Overview 30
Idylla NRAS Mutation Test 31
Idylla NRAS Mutation Test Product Overview 31
Idylla NRAS-BRAF Mutation Test 32
Idylla NRAS-BRAF Mutation Test Product Overview 32
Idylla Retrieve – NGS Hotspot Panel Assay 33
Idylla Retrieve – NGS Hotspot Panel Assay Product Overview 33
Idylla Sepsis Assay 34
Idylla Sepsis Assay Product Overview 34
Idylla Solid Biopsy Test – Breast Cancer 35
Idylla Solid Biopsy Test – Breast Cancer Product Overview 35
Idylla Syndromic Immunocompromised Panel 36
Idylla Syndromic Immunocompromised Panel Product Overview 36
Idylla Syndromic Panel – Tropical Fever 37
Idylla Syndromic Panel – Tropical Fever Product Overview 37
Idylla System – Multiplex Companion Diagnostics Test 38
Idylla System – Multiplex Companion Diagnostics Test Product Overview 38
Idylla Viral Load Assay – HBV 39
Idylla Viral Load Assay – HBV Product Overview 39
Idylla Viral Load Assay – HCV 40
Idylla Viral Load Assay – HCV Product Overview 40
Idylla Viral Load Assay – HIV 41
Idylla Viral Load Assay – HIV Product Overview 41
SeptiCyte Triage 42
SeptiCyte Triage Product Overview 42
Biocartis Group NV – Key Competitors 43
Biocartis Group NV – Key Employees 44
Biocartis Group NV – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Biocartis Group NV, Recent Developments 46
Jul 17, 2018: Biocartis launches innovative Idylla MSI Assay 46
Jun 27, 2018: Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases 46
May 28, 2018: Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests 47
May 17, 2018: Biocartis Group: Two Performance Studies on Idylla MSI Biomarkers Selected for Publication at ASCO Conference 47
Apr 26, 2018: Biocartis Q1 2018 Business Update 48
Mar 15, 2018: Biocartis Abstract on Performance Idylla ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting 50
Mar 01, 2018: Biocartis Announces 2017 Results and 2018 Outlook 50
Mar 01, 2018: Biocartis Establishes R&D Center in the US 53
Mar 01, 2018: European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects 54
Feb 26, 2018: EPD Obtains European Regulatory Approval for Its Cardiac Mapping and Navigation System 55
Appendix 56
Methodology 56
About GlobalData 59
Contact Us 59
Disclaimer 59
Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview 6
Biocartis Group NV Pipeline Products by Equipment Type 7
Biocartis Group NV Pipeline Products by Indication 8
Biocartis Group NV, Key Facts 9
Biocartis Group NV, Major Products and Services 10
Biocartis Group NV Number of Pipeline Products by Development Stage 11
Biocartis Group NV Pipeline Products Summary by Development Stage 12
EGFR Colon Cancer Test - Product Status 14
EGFR Colon Cancer Test - Product Description 14
Idylla Blood Stream Infections Panel - Product Status 15
Idylla Blood Stream Infections Panel - Product Description 15
Idylla ctEGFR Assay - Product Status 16
Idylla ctEGFR Assay - Product Description 16
Idylla Extended KRAS Mutation Test - Product Status 17
Idylla Extended KRAS Mutation Test - Product Description 17
Idylla Extended NRAS Mutation Test - Product Status 18
Idylla Extended NRAS Mutation Test - Product Description 18
Idylla HPV Test - Head & Neck Cancer - Product Status 19
Idylla HPV Test - Head & Neck Cancer - Product Description 19
Idylla Immuno Tx Panel Test - Product Status 20
Idylla Immuno Tx Panel Test - Product Description 20
Idylla KRAS Mutation Test - Product Status 21
Idylla KRAS Mutation Test - Product Description 21
Idylla Liquid Biopsy EGFR Mutation Assay - Product Status 22
Idylla Liquid Biopsy EGFR Mutation Assay - Product Description 22
Idylla Liquid Biopsy Test - Breast Cancer - Product Status 23
Idylla Liquid Biopsy Test - Breast Cancer - Product Description 23
Idylla Meningitis Assay - Product Status 24
Idylla Meningitis Assay - Product Description 24
Idylla MERS Assay - Product Status 25
Idylla MERS Assay - Product Description 25
Idylla MSI Test - Product Status 26
Idylla MSI Test - Product Description 26
Idylla Multiplex Respiratory Panel - Product Status 27
Idylla Multiplex Respiratory Panel - Product Description 27
Idylla Neuro Panel Test - Product Status 28
Idylla Neuro Panel Test - Product Description 28
Idylla Neurological Disease Assay - Product Status 29
Idylla Neurological Disease Assay - Product Description 29
Idylla NGS Prep Panel - Pan-Tumor - Product Status 30
Idylla NGS Prep Panel - Pan-Tumor - Product Description 30
Idylla NRAS Mutation Test - Product Status 31
Idylla NRAS Mutation Test - Product Description 31
Idylla NRAS-BRAF Mutation Test - Product Status 32
Idylla NRAS-BRAF Mutation Test - Product Description 32
Idylla Retrieve - NGS Hotspot Panel Assay - Product Status 33
Idylla Retrieve - NGS Hotspot Panel Assay - Product Description 33
Idylla Sepsis Assay - Product Status 34
Idylla Sepsis Assay - Product Description 34
Idylla Solid Biopsy Test - Breast Cancer - Product Status 35
Idylla Solid Biopsy Test - Breast Cancer - Product Description 35
Idylla Syndromic Immunocompromised Panel - Product Status 36
Idylla Syndromic Immunocompromised Panel - Product Description 36
Idylla Syndromic Panel - Tropical Fever - Product Status 37
Idylla Syndromic Panel - Tropical Fever - Product Description 37
Idylla System - Multiplex Companion Diagnostics Test - Product Status 38
Idylla System - Multiplex Companion Diagnostics Test - Product Description 38
Idylla Viral Load Assay - HBV - Product Status 39
Idylla Viral Load Assay - HBV - Product Description 39
Idylla Viral Load Assay - HCV - Product Status 40
Idylla Viral Load Assay - HCV - Product Description 40
Idylla Viral Load Assay - HIV - Product Status 41
Idylla Viral Load Assay - HIV - Product Description 41
SeptiCyte Triage - Product Status 42
SeptiCyte Triage - Product Description 42
Biocartis Group NV, Key Employees 44
Biocartis Group NV, Subsidiaries 45
Glossary 58
List of Figures
Biocartis Group NV Pipeline Products by Equipment Type 7
Biocartis Group NV Pipeline Products by Development Stage 11